28
Thu, Mar
51 New Articles

Sayenko Kharenko Obtains Merger Clearance in Ukraine for Boehringer Ingelheim's Asset Swap Transaction with Sanofi

Sayenko Kharenko Obtains Merger Clearance in Ukraine for Boehringer Ingelheim's Asset Swap Transaction with Sanofi

Ukraine
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

Sayenko Kharenko's antitrust team has provided legal assistance in obtaining merger clearance with the Antimonopoly Committee of Ukraine (AMC) for the EUR 22.8 billion acquisition of Sanofi’s animal health business (“Merial”) by Boehringer Ingelheim through an asset swap in exchange for Boehringer Ingelheim’s consumer healthcare business. The transaction is expected to close in Q4 2016, subject to appropriate regulatory approvals globally.

According to Sayenko Kharenko, "the transaction would allow Sanofi to become a global leader in consumer healthcare. Whereas combining Merial’s and Boehringer Ingelheim’s complementary strengths would create the second largest player in the global animal health market."

The Boehringer Ingelheim pharmaceutical company, which is headquartered in Ingelheim, Germany, operates globally through 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, which was founded in 1885, is researching, developing, manufacturing, and marketing new medications of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim Consumer Healthcare is the eighth largest consumer healthcare business in the world.

The Sanofi healthcare company discovers, develops, and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and the Merial animal health company. Merial employs 6,900 people and operates in more than 150 countries worldwide.

According to Sayenko Kharenko, "after examining the proposed transaction, the AMC has concluded that its implementation poses neither threat to competition nor significantly limits competition on any product market in Ukraine."

Sayenko Kharenko’s competition team on the project was led by Partner Vladimir Sayenko and included Counsel Maksym Nazarenko and Associates Julia Kuyda and Igor Pomaz.

Our Latest Issue